logo
Sign in

MYMX Stock Price, Chart, Stats & News

Mymetics Corporation
Save

Mymetics Corporation (MYMX) does not currently pay a dividend.

46
Market cap
Current P/E
Forward P/E

MYMX chart

1M
3M
1Y
5Y
Loading chart...

About

Health care
Sector
Biotechnology
Industry

Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent.

Similar securities

Based on sector and market capitalization

Report issue